BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 27, 2008
View Archived Issues
Ranbaxy receives Indian approval for phase III clinical trial of antimalaria drug RBx-11160
Read More
Toxicity of antispastic agent azumolene evaluated in vivo
Read More
New antimicrobial agents reported in recent patent literature
Read More
Oramed launches phase Ia insulin suppository trial
Read More
Novel agents for cardiovascular disorders disclosed in recent patents
Read More
Early results from first clinical study of JNJ-26854165 reported
Read More
Oxygen to conduct safety and efficacy clinical trial of Oxycyte in TBI
Read More
Anti-VEGFR-1 monoclonal antibody IMC-18F1 well tolerated thus far in phase I study
Read More
Columbia signs collaboration agreement with NIH for phase III PREGNANT study of Prochieve
Read More
Activity of anticancer CDK inhibitor AZD-5597 described
Read More
Calando completes phase I clinical study of IT-101 in inoperable or metastatic tumors
Read More
Pramiconazole demonstrates efficacy in vulvovaginal yeast infections
Read More
Activity of potent PI3K inhibitor GSK-615 disclosed
Read More
New treatment options for gastrointestinal disorders imparted in recent patents
Read More
Recent Biovitrum and Merck patents describe new therapeutic agents for obesity
Read More
Phenomix and Forest sign development and commercialization agreement for dutogliptin
Read More
GSK and Affiris sign exclusive license and option agreement for therapeutic AD vaccines
Read More
FDA approves Alchemia's IND application for phase III clinical trials of HyCAMP
Read More
SkyePharma announces successful completion of phase III study of Flutiform
Read More
Astellas withdraws European MAA for telavancin and plans resubmission
Read More
Johnson & Johnson submits NDA to FDA for carisbamate
Read More
EMEA issues positive opinion for Lunivia MAA in Europe
Read More
Further clinical trials suspended for GRC-6211 in osteoarthritis pain
Read More
Astellas' Graceptor launched in Japan
Read More
CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia
Read More